FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Carvykti Improves Survival in Phase 3 Trial: J&J

[ Price : $8.95]

J&J touts positive overall survival results of its Carvykti in a Phase 3 trial in patients with relapsed or lenalidomide-refractor...

Checkpoint Resubmits Cosibelimab BLA

[ Price : $8.95]

Checkpoint Therapeutics says it has completed the resubmission of a BLA for its cosibelimab cancer treatment.

FDA OKs Pyzchiva as Stelara Biosimilar

[ Price : $8.95]

FDA approves Samsung Bioepis Pyzchiva as an interchangeable biosimilar for Janssens Stelara.

FDA OKs Genentechs Vabysmo Syringe

[ Price : $8.95]

FDA approves a Genentech Vabysmo prefilled syringe to treat three retinal disorders with the same medicine as Vabysmo vials.

FDA Drops Interchangeability Switching Studies

[ Price : $8.95]

Venable attorney Robert Schwartz says an updated FDA guidance with alternatives to switching studies for demonstrating biosimilar ...

CGMP Violations in Sun Pharmaceutical Inspection

[ Price : $8.95]

FDA warns Indias Sun Pharmaceutical Industries about repeat CGMP violations at one drug manufacturing facility and in other compan...

Opportunities, Risks in SCOTUS End to Chevron Deference: Lawyers

[ Price : $8.95]

Attorneys in several law firms analyze the opportunities and risks for FDA-regulated companies arising from the Supreme Court deci...

Web Site Illegally Selling Semaglutide Products: FDA

[ Price : $8.95]

FDA warns the ozempen.com Web site to stop offering unapproved and misbranded drugs to U.S. consumers.

FDA OKs New Lilly Alzheimers Drug

[ Price : $8.95]

FDA approves Lillys Kisunla injection to treat Alzheimers disease.

Plan Now to Adopt FDA Trial Diversity Guide: Lawyers

[ Price : $8.95]

Five Hogan Lovells attorneys analyze a new FDA draft guidance on clinical trial diversity action plans and urge companies to begin...